Select Bibliography

Filter by any of these (after searching):

Lafky, J. M.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 9 items

Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR).

Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - NCCTG-N0776

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

Freedman, Rachel A. , Seisler, D. K. , Foster, J. C. , Sloan, J. A. ... - - Breast Cancer Res Treat - 2017

Manuscript - Primary - Primary - Older Adult - A151511 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741

NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary - Primary - Neuro-Onc - N0776

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Uhm, J. , Giannini, C. ... - - Clin Cancer Res - 2013

Manuscript - Primary - Primary - Neuro-Onc - NCCTG-N0776

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C

Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J Clin Oncol - 2010

Abstract - Primary - Primary - GI - N054C

Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib

Lafky, J. M. , Anderson, S. K. , Morlan, B. W. , Nelson, G. D. ... - AACR - Cancer Res - 2012

Abstract - Secondary-not-in-original - Primary - GI - N054C

Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib

Lafky, J. M. , Bot, B. M. , Morlan, B. W. , Anderson, S. K. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary-not-in-original - Primary - GI - N054C

Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831

Moreno-Aspitia, A. , Hillman, D. W. , Dueck, A. C. , Carney, W. P. ... - ASCO - J Clin Oncol - 2009

Abstract - Secondary - Primary - Breast - N9831

Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy with or without trastuzumab: Results from the NCCTG adjuvant trial N9831

Moreno-Aspitia, A. , Hillman, D. W. , Dyar, S. H. , Tenner, K. S. ... - - Cancer - 2013

Manuscript - Secondary - Primary - Breast - N9831